Phase 4 Stroke Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older
- People who had little or no disability before their stroke (as measured by a standard disability scale called the modified Rankin Scale, with a score of 0 or 1)
- People whose stroke symptoms started within 4.5 hours of when they were last known to be well
- People with a stroke severity score of 4 or higher on a standard medical scale used to measure stroke symptoms (called the NIHSS)
- People whose symptoms did not improve enough, or got worse, within 1 hour of receiving the standard clot-dissolving treatment given through a drip (intravenous thrombolysis) — specifically, where the stroke severity score did not drop by 2 or more points, or increased by 1 or more points
- People who are not planned for, or are not eligible for, a procedure to physically remove the clot (called endovascular treatment)
- People who, or whose legally authorised representative, are able to provide written consent to participate
Who may not be able to join:
- People whose brain scans show bleeding in the brain before they are enrolled in the trial
- People whose brain condition is caused by something other than a blood clot, such as a blood vessel malformation, aneurysm, brain tumour, abscess, or a condition affecting the nerve coverings (demyelinating disease)
- People who have a significant narrowing in a large or medium brain artery that would require a clot-removal procedure or a clot-dissolving treatment delivered directly into the artery
- People who cannot safely receive the study drug tirofiban, including those with: a known allergy to tirofiban; severely reduced liver function; severely reduced kidney function; advanced heart failure (classified as NYHA class III or IV); bleeding disorders or a history of serious bleeding; a history of low platelet or white blood cell counts; previous drug-related blood or liver problems; or current blood counts that are too low (confirm specific values with trial site)
- People who have already received tirofiban or a similar type of medication (called GP IIb/IIIa inhibitors) before enrolment, or for whom such medications are already planned
- People whose stroke is clearly caused by a heart problem, such as atrial fibrillation, a faulty heart valve, a blood clot in the heart, a recent heart attack (within the past 3 months), or significantly reduced heart pumping function, among other cardiac conditions (confirm full list with trial site)
- People who are pregnant or breastfeeding
- People whose life expectancy is less than 6 months
- People with existing neurological or psychiatric conditions that could affect how outcomes are measured
- People who are unlikely to be available for a follow-up assessment at 90 days
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +8613716292262
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Proportion of patients with mRS 0-2 at 90 days; Symptomatic Intracranial Hemorrhage (sICH) within 48 hours
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.